Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 18/20 | 0.61 |
| ▸ | CTSL | P07711 | 11/20 | 0.58 |
| ▸ | CTSS | P25774 | 9/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSV | O60911 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154653 | 0.86 | CTSK (0.64) | CTSKCTSLCTSSCTSV | |
| SCHEMBL13677208 | 0.86 | CTSK (0.64) | CTSKCTSLCTSSCTSV | |
| SCHEMBL4451492 | 0.86 | CTSK (0.64) | CTSKCTSLCTSSCTSV | |
| SCHEMBL6807727 | 0.86 | CTSK (0.64) | CTSKCTSLCTSSCTSV | |
| SCHEMBL4453013 | 0.84 | CTSK (0.61) | CTSKCTSLCTSSCTSV | |
| SCHEMBL7200569 | 0.84 | CTSK (0.61) | CTSKCTSLCTSSCTSV | |
| SCHEMBL13677249 | 0.84 | CTSK (0.61) | CTSKCTSLCTSSCTSV | |
| SCHEMBL4451358 | 0.84 | CTSK (0.61) | CTSKCTSLCTSSCTSV | |
| SCHEMBL12828388 | 0.84 | CTSK (0.80) | CTSKCTSLCTSSCTSV | |
| SCHEMBL6808367 | 0.84 | CTSK (0.80) | CTSKCTSLCTSSCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112089-A1 | Cysteine Protease Inhibitors | MEDIVIR AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-7915300-B2 | Especially those of papain superfamily; prophylaxis or treatment of disorders stemming from misbalance of physiological proteases such as cathepsin K; (3aS,6S,6aS)-6-Fluoro-4-{(S)-4-methyl-2-[(R)-2,2,2-trifluoro-1-(4'-methanesulfonylbiphenyl-4-yl)-ethylamino]-pentanoyl}-tetrahydro-furo[3,2-b]pyrrol-3-one | MEDIVIR AB (SE) | 2011-03-29 | — | — | US | disclosed |
| US-20080234260-A1 | Cysteine Protease inhibitors | MEDIVIR AB (SE) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234260-A1 | Cysteine Protease inhibitors | CTSS, CTSZ, CTSK | CTSK 3/4885CTSL 10/4885CTSS 1/4885 |
| US-20110112089-A1 | Cysteine Protease Inhibitors | CTSS, CTSZ, CTSK | CTSK 3/4885CTSL 11/4885CTSS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.